Full Text of HR0588 103rd General Assembly
HR0588 103RD GENERAL ASSEMBLY | | | HR0588 | | LRB103 35954 MST 66041 r |
|
| 1 | | HOUSE RESOLUTION | 2 | | WHEREAS, Many people living with serious mental illnesses, | 3 | | including bipolar disorder, major depressive disorder, | 4 | | schizophrenia, and schizoaffective disorder or | 5 | | gastrointestinal disorders such as gastroparesis, upset | 6 | | stomach, nausea, and vomiting, may be treated with medications | 7 | | that work as dopamine receptor blocking agents, including | 8 | | antipsychotics and antiemetics; and | 9 | | WHEREAS, While ongoing treatment with these medications | 10 | | can be necessary, prolonged use is associated with tardive | 11 | | dyskinesia (TD), an involuntary movement disorder that is | 12 | | characterized by uncontrollable, abnormal, and repetitive | 13 | | movements of the face, torso, limbs, and fingers or toes; and | 14 | | WHEREAS, Even mild symptoms of TD can impact people | 15 | | physically, socially, and emotionally; and | 16 | | WHEREAS, It is estimated that TD affects approximately | 17 | | 600,000 people in the United States, and approximately 65 | 18 | | percent of people with TD have not been diagnosed, making it | 19 | | important to raise awareness about the symptoms; and | 20 | | WHEREAS, It is important that people taking these | 21 | | medications be monitored for TD by a healthcare provider; |
| | | HR0588 | - 2 - | LRB103 35954 MST 66041 r |
|
| 1 | | regular screening for TD is recommended by the American | 2 | | Psychiatric Association; and | 3 | | WHEREAS, Clinical research has led to approval of | 4 | | treatments for adults with TD by the U.S. Food and Drug | 5 | | Administration, and recognition and treatment of TD can make a | 6 | | positive impact in the lives of many people experiencing | 7 | | psychotic and mood disorders; and | 8 | | WHEREAS, The Illinois House of Representatives can utilize | 9 | | its position to raise awareness of TD among the public and | 10 | | medical community; therefore, be it | 11 | | RESOLVED, BY THE HOUSE OF REPRESENTATIVES OF THE ONE | 12 | | HUNDRED THIRD GENERAL ASSEMBLY OF THE STATE OF ILLINOIS, that | 13 | | we declare May 5-11, 2024 as "Tardive Dyskinesia Awareness | 14 | | Week" in the State of Illinois; and be it further | 15 | | RESOLVED, That we encourage anyone experiencing | 16 | | uncontrollable, abnormal, and repetitive movements to consult | 17 | | their healthcare provider regarding their symptoms. |
|